Analyst consensus rating
Theravance Biopharma Analyst Rating: Hold
TBPH is rated Hold by 3 analysts with a $17.67 target. As of 2026-08-20.
Direct answer
Theravance Biopharma's consensus rating is Hold.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.67.
Forecast evidence checked August 20, 2026.
Get free Theravance Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.95
- Average price target
- $17.67
- High price target
- $19.00
- Low price target
- $17.00
- Low target gap
- +0.3%
- Target upside
- +4.2%
- High target gap
- +12.1%
- Target range width
- 11.8%
- Consensus rating
- Hold
- Analysts
- 3
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Theravance Biopharma?
Theravance Biopharma has a verified Hold consensus. The same dataset has an average price target of $17.67.
How far are Theravance Biopharma's low and high targets from the recorded price?
The low target implies +0.3%, while the high target implies +12.1%.
How many analysts are included in Theravance Biopharma's consensus?
The verified consensus includes 3 analysts.
How is Theravance Biopharma's target upside or downside calculated?
The average target of $17.67 is divided by the recorded price of $16.95, then one is subtracted to produce +4.2%. This does not guarantee a future return.
When was Theravance Biopharma's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.